Condition or Therapy:
Autism spectrum disorder
What is the goal of this study?
This is a multi-center clinical study that will ask if an investigational drug can improve the social communication and interaction skills of children and teens who have autism spectrum disorder (ASD). This drug blocks a brain hormone receptor (V1a) that may be related to socialization, anxiety, stress, and aggression. This drug has been studied in adults with ASD (our study team was also a part of this adult study).
Who can join the study?
This is just for kids between 5 and 17 who have been diagnosed with ASD, speak fluent English (both subject and at least one parent/legal guardian) and are ‘high-function’ (IQ 70 and higher).
What happens in the study?
Eligible participants will be randomly assigned to three groups: placebo, low dose, and high dose. Participants will receive one of these three medications for 24 weeks. Participants will come into Seattle Children’s around once every 6 weeks (about 7 times in total) so that we can assess their general health and ASD symptoms. In between those clinic visits, a nurse will need to take some additional blood samples, either at your home or at the clinic.
Who can I contact for information or to enroll?
Contact the research coordinator by email or at 206-987-5476.
Seattle Children's main campus
Dr. Soo Kim